Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Nasopharyngeal Neoplasms 1Mesothelioma 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Bone Neoplasms 1

Interventions

pembrolizumab 2Zoledronic Acid 2Radiation 2tocilizumab 1saracatinib 1poly ICLC 1pegylated granulocyte colony-stimulating factor 1montanide ISA 51 1liposomal doxorubicin 1fludarabine 1flt3 ligand protein 1cc-486 1aldesleukin 1Taxes 1Surveys and Questionnaires 1Standard of Care 1Radiotherapy 1Quality of Life 1Psychology, Positive 1Practice Guidelines as Topic 1Patient Reported Outcome Measures 1Palliative Care 1Paclitaxel 1Observation 1Nivolumab 1Molecular Diagnostic Techniques 1Methods 1Lomustine 1Irinotecan 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × tocilizumab × Breast × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡